Electro-Optical Sciences Appoints Charles Stiefel to Board of Directors

IRVINGTON, NY--(Marketwire - January 11, 2010) - Electro-Optical Sciences, Inc. ("EOS") (NASDAQ: MELA) today announced the appointment of Charles Stiefel to its Board of Directors. Mr. Stiefel brings more than 25 years of experience in the dermatology industry to the EOS Board.

"Charlie brings a wealth of experience that is particularly valuable to Electro-Optical Sciences at this time," said Joseph V. Gulfo, MD, President and CEO of Electro-Optical Sciences. "As we prepare for the potential approval and launch of MelaFind, we are transitioning from an R&D-focused organization to a commercial business. We anticipate facing business and strategic challenges, opportunities, and decisions similar to those that Charlie has addressed with great success time and time again in his career. His insight will prove invaluable to EOS as we move forward with our plans for MelaFind, our breakthrough non-invasive, point of care, computerized system for early melanoma detection."

Mr. Stiefel served as the Chairman and CEO of Stiefel Laboratories, Inc. from 2001 to July 2009 when he stepped down after overseeing GlaxoSmithKline's successful acquisition of the company. He joined Stiefel Laboratories as General Counsel in 1982 and was subsequently named Executive Vice President and then President of the company. He had served as a member of Stiefel Laboratories' Board of Directors since 1975. At the time of GSK's acquisition in March of 2009, Stiefel was the largest privately-held dermatology company in the world.

In 2003, the South Florida Dermatology Foundation awarded him the Lifetime Achievement Award, and he was named Ernst & Young's Entrepreneur of the Year in Health Sciences for the State of Florida in 2006. In 2007, the American Academy of Dermatology honored him with its Distinguished Service Award.

Mr. Stiefel earned his B.S. degree at Yale University, and was valedictorian of his class at Albany Law School.

Mr. Stiefel's appointment is effective immediately. This additional appointment will fill EOS' ninth and final board seat.

About Electro-Optical Sciences

Electro-Optical Sciences is a medical technology company focused on developing MelaFind®, a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. EOS designed MelaFind® to assist in the evaluation of pigmented skin lesions, including atypical moles, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind® acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma.

Although the MelaFind® PMA is subject to the FDA's expedited review procedures, EOS cannot predict either the timing of the FDA's decision on the PMA application or the outcome. FDA approval is required prior to marketing MelaFind® in the United States.

For more information on EOS, visit www.eosciences.com.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors.

Contact Information: For further information contact: Investors David Carey Lazar Partners Ltd. 212-867-1768 Media Hollister Hovey Lazar Partners Ltd. 646-871-8482